Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This letter to the editor raises concerns about minoxidil, an arterial vasodilator also used for androgenic alopecia, noting that overdose can cause severe side effects such as distributive shock, pulmonary edema, and myocardial ischemia.

This research found that prolonged doses of Amlodipine at 5mg/kg BW or higher impaired fertility indicators in adult male rats, affecting sperm morphology, count, and motility.

This article describes the efficient synthesis of (S)-N-(2-bromo-6-methoxypyridin-4-yl)-2-hydroxy-2,4-dimethylpentanamide, a novel topical antiandrogen, with high purity and enantiomeric excess but reports no pharmacological results.

This study reported that derivatization with 5-butylpicolinic acid improved the sensitivity for detecting testosterone and DHT in saliva using LC-ESI-MS/MS, with minimal interference from the saliva matrix.

In this study, the pharmacological action of dobutamine on rabbit retinae was found to be distinct from that of other dopamine analogs like apomorphine and N-methyl-dopamine.

These drugs raise prostaglandin-like material in dog blood, possibly causing blood vessel widening.

This review highlights advancements in the synthesis and biological applications of 2,5-Diazabicyclo[2.2.1]heptane, a scaffold in medicinal chemistry, focusing on its construction strategies and potential use in treatments for cancer, neurological disorders, and infections.

The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This review discusses hypersensitivity reactions to anticoagulants like ASA and heparins, highlighting their rare but potentially life-threatening nature, and emphasizes the need for meticulous allergy testing to find safe alternatives.

Olanzapine reduces stress-related anxiety in rats when given acutely.

This symposium reviewed strategies to advance stalled drug molecules, discussed common regulatory hurdles, and explored options for repurposing drugs, but it reported no new research findings.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

Finasteride boosts morphine's pain relief, stops tolerance, and reduces withdrawal in rats.

This guideline summary, endorsed by six Spanish pediatric societies, outlines consensus recommendations for managing childhood asthma, emphasizing diagnosis, maintenance treatment with low-dose inhaled corticosteroids, and patient education for effective control.

In this study, a biocompatible zinc oxide nanocomposite loaded with the anticancer drug 9-Br-Nos demonstrated effective drug delivery and cytotoxicity against lung cancer cells in vitro, while also proving non-toxic to healthy cells, suggesting its potential for targeted lung cancer treatment.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.

This study developed and validated a method using UPLC-PDA and LC-Q-TOF/MS to identify and measure prohibited substances in dietary supplements, showing reliable detection of compounds like minoxidil and finasteride.

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

In this study, researchers developed microparticle-embedded gas-propelled microneedles that showed higher drug loading and transdermal delivery efficiency compared to traditional microneedles.

This study suggests that repeated trilostane treatment increases brain allopregnanolone levels and delays epileptogenesis in rats after status epilepticus.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.

This study reported that a novel nanomedicine combining berberine and sinapic acid significantly inhibited the growth of mouse mammary carcinoma cells and demonstrated an anti-tumor effect in vivo, without significant systemic toxicity after 28 days, suggesting a promising, low-toxicity therapeutic strategy for breast cancer.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.